Search Within

MULTIPLE MYELOMA
Results 1 - 201 of 201
First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dellAdulto) Multiple Myeloma Working Party Perspective

Journal: Current Drug Targets
Volume: 10,Issue: 10
Page: 906-922
Authors: Pellegrino Musto, Fiorella D'Auria, Giuseppe Pietrantuono, Luca Baldini, Sara Bringhen, Tommaso Caravita, Francesco Di Raimondo, Fortunato Morabito, Massimo Offidani, Maria Teresa Petrucci, Patrizia Tosi, Francesca Gay, Michele Cavo, Mario Boccadoro and Antonio Palumbo

Bisphosphonate Therapy in the Treatment of Multiple Myeloma

Journal: Current Pharmaceutical Design
Volume: 16,Issue: 27
Page: 3028-3036
Authors: M. A. Lawson, J. Ashcroft and P. I. Croucher

The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma

Journal: Current Pharmaceutical Design
Volume: 20,Issue: 1
Page: 125-135
Authors: Jie Li, Jingyu Zhu, Biyin Cao and Xinliang Mao

Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma

Journal: Current Medicinal Chemistry
Volume: 21,Issue: 27
Page: 3173-3187
Authors: J. Zhu, M. Wang, B. Cao, T. Hou and X. Mao

Interferon-Alpha in the Treatment of Multiple Myeloma

Journal: Current Drug Targets
Volume: 12,Issue: 3
Page: 437-446
Authors: Teh Liane Khoo, Annette Juul Vangsted, Douglas Joshua and John Gibson

Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma

Journal: Letters in Drug Design & Discovery
Volume: 1,Issue: 2
Page: 135-136
Authors: Domenico Ribatti and Angelo Vacca

Clinical Experience with Thalidomide and Lenalidomide in Multiple Myeloma

Journal: Current Cancer Drug Targets
Volume: 12,Issue: 4
Page: 372-390
Authors: T. Moehler

Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis

Journal: Current Angiogenesis (Discontinued)
Volume: 2,Issue: 2
Page: 76-95
Authors: Michael G. Alexandrakis and George Tsirakis

Evolving Treatments in Multiple Myeloma Patients with Renal Failure

Journal: Reviews on Recent Clinical Trials
Volume: 9,Issue: 4
Page: 276-279
Authors: Alessandro Gozzetti, Giulia Papini, Veronica Candi and Monica Bocchia

Thromboembolism with Immunomodulatory Agents in the Treatment of Multiple Myeloma

Journal: Cardiovascular & Hematological Agents in Medicinal Chemistry
Volume: 9,Issue: 1
Page: 7-13
Authors: Anurag Singh and Ajeet Gajra

Novel Targeted Therapies and Combinations for the Treatment of Multiple Myeloma

Journal: Cardiovascular & Hematological Disorders-Drug Targets
Volume: 13,Issue: 1
Page: 2-15
Authors: Amit Agarwal and Daruka Mahadevan

Oleocanthal Inhibits Proliferation and MIP-1α Expression in Human Multiple Myeloma Cells

Journal: Current Medicinal Chemistry
Volume: 20,Issue: 19
Page: 2467-2475
Authors: M. Scotece, R. Gomez, J. Conde, V. Lopez, J.J. Gomez-Reino, F. Lago, A.B. Smith III and O. Gualillo

Identification of New Targets for Therapy of Osteolytic Bone Disease in Multiple Myeloma

Journal: Current Drug Targets
Volume: 6,Issue: 6
Page: 701-711
Authors: O. Hjertner, T. Standal, M. Borset, A. Sundan and A. Waage

Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients

Journal: Current Cancer Therapy Reviews
Volume: 9,Issue: 1
Page: 1-7
Authors: Alessandra Romano, Giuseppina Uccello, Paolo Spina, Rosario Cunsolo, Calogero Vetro and Francesco Di Raimondo

Targeting Signaling Pathways in Multiple Myeloma

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 6
Page: 407-413
Authors: Cavallo Federica, Palumbo Antonio, Tricot Guido and Boccadoro Mario

Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 6
Page: 449-453
Authors: Maurizio Zangari, Federica Cavallo and Guido Tricot

Antiangiogenic Therapeutic Approaches in Multiple Myeloma

Journal: Current Cancer Drug Targets
Volume: 12,Issue: 7
Page: 768-775
Authors: Domenico Ribatti, Giuseppe Mangialardi and Angelo Vacca

miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF

Journal: Current Cancer Drug Targets
Volume: 16,Issue: 9
Page: 807-817
Authors: Benping Zhang, Ling Ma, Jia Wei, Jingyu Hu, Zichu Zhao, Youping Wang, Yan Chen and Fei Zhao

Thalidomide in Multiple Myeloma

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 6
Page: 431-440
Authors: T. M. Moehler, J. Hillengass, A. Glasmacher and H. Goldschmidt

The Impact of New Emerging Drugs in the Treatment of Multiple Myeloma:Is there Still a Role for PBSC Transplantation?

Journal: Current Stem Cell Research & Therapy
Volume: 2,Issue: 1
Page: 1-11
Authors: Alessandro Corso and Marzia Varettoni

New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors

Journal: Current Pharmaceutical Design
Volume: 19,Issue: 4
Page: 734-744
Authors: Michele Cea, Antonia Cagnetta, Marco Gobbi, Franco Patrone, Paul G. Richardson, Teru Hideshima and Kenneth C. Anderson

Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis

Journal: Current Molecular Medicine
Volume: 14,Issue: 4
Page: 423-431
Authors: J. Abdi, J. Garssen and F. Redegeld

A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma

Journal: Current Medicinal Chemistry
Volume: 24,Issue: 25
Page: 2736-2744
Authors: Annalisa Mercurio , Giulia Adriani , Alessia Catalano , Alessia Carocci , Luigia Rao , Giovanni Lentini , Maria M. Cavalluzzi , Carlo Franchini , Angelo Vacca and Filomena Corbo *

Novel Targets and Derived Small Molecule Inhibitors in Multiple Myeloma

Journal: Current Cancer Drug Targets
Volume: 12,Issue: 7
Page: 797-813
Authors: Klaus Podar

From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario

Journal: Current Drug Targets
Volume: 14,Issue: 10
Page: 1144-1149
Authors: Marco Rossi, Nicola Amodio, Maria Teresa Di Martino, Daniele Caracciolo, Pierosandro Tagliaferri and Pierfrancesco Tassone

Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials

Journal: Reviews on Recent Clinical Trials
Volume: 11,Issue: 2
Page: 124-127
Authors: Alessandro Gozzetti

Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma

Journal: Current Cancer Drug Targets
Volume: 17,Issue: 9
Page: 839-845
Authors: Djordje Atanackovic, Tim Luetkens, Sabari Radhakrishnan and Nicolaus Kroger*

Recent Advances in the Treatment of Multiple Myeloma

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 5
Page: 381-393
Authors: Hiroshi Yasui, Teru Hideshima, Paul G. Richardson and Kenneth C. Anderson

Gene therapy for Multiple Myeloma

Journal: Current Gene Therapy
Volume: 8,Issue: 4
Page: 247-255
Authors: Yasuo Adachi, Naoko Yoshio-Hoshino and Norihiro Nishimoto

Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies

Journal: Current Cancer Drug Targets
Volume: 11,Issue: 9
Page: 1005-1024
Authors: K. Podar and K. C. Anderson

Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma

Journal: Current Cancer Drug Targets
Volume: 12,Issue: 7
Page: 814-822
Authors: P. Tassone, P. Neri, R. Burger, M. T. Di Martino, E. Leone, N. Amodio, M. Caraglia and P. Tagliaferri

MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches

Journal: Current Pharmaceutical Biotechnology
Volume: 15,Issue: 5
Page: 459-467
Authors: Marco Rossi, Nicola Amodio, Maria Teresa Di Martino, Pierosandro Tagliaferri, Pierfrancesco Tassone and William C. Cho

Cellulitis-Like Sweet Syndrome Preceding Multiple Myeloma. A Case Report

Journal: Clinical Immunology, Endocrine & Metabolic Drugs
Volume: 2,Issue: 1
Page: 52-55
Authors: Hakan S. Sayiner, Birgül Tepe, Halil Erdoğdu and M. Özgür Çevik

Immunomodulatory Drugs (IMiDs) in Multiple Myeloma

Journal: Current Cancer Drug Targets
Volume: 17,Issue: 9
Page: 846-857
Authors: Shahzad Raza, Rachael A. Safyan and Suzanne Lentzsch*

New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway

Journal: Current Pharmaceutical Design
Volume: 12,Issue: 3
Page: 327-340
Authors: Niels W.C.J. van de Donk, Andries C. Bloem, Ellen v. d. Spek and Henk M. Lokhorst

Treatment Strategies for Multiple Myeloma in the Age of Novel Therapies

Journal: Current Cancer Therapy Reviews
Volume: 2,Issue: 2
Page: 169-183
Authors: Laurence Catley and Kenneth C. Anderson

Antiestrogenic Therapies in Solid Cancers and Multiple Myeloma

Journal: Current Molecular Medicine
Volume: 6,Issue: 4
Page: 359-368
Authors: Brigitte Sola and Jack-Michel Renoir

Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy

Journal: Current Cancer Drug Targets
Volume: 9,Issue: 7
Page: 854-870
Authors: P. Tassone, P. Tagliaferri, M. Rossi, T. Calimeri, A. Bulotta, A. Abbruzzese, M. Caraglia and P. Neri

Bisphosphonate Anticancer Activity in Multiple Myeloma

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 12,Issue: 2
Page: 123-128
Authors: Evangelos Terpos

Targeted Therapy of Multiple Myeloma: The Changing Paradigm at the Beginning of the New Millennium

Journal: Current Cancer Drug Targets
Volume: 12,Issue: 7
Page: 743-756
Authors: Fortunato Morabito, Anna Grazia Recchia, Carla Mazzone and Massimo Gentile

Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma

Journal: Current Cancer Drug Targets
Volume: 12,Issue: 7
Page: 776-796
Authors: Paola Neri and Nizar J. Bahlis

MicroRNAs in the Pathobiology of Multiple Myeloma

Journal: Current Cancer Drug Targets
Volume: 12,Issue: 7
Page: 823-837
Authors: Marta Lionetti, Luca Agnelli, Luigia Lombardi, Pierfrancesco Tassone and Antonino Neri

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma

Journal: Current Cancer Drug Targets
Volume: 12,Issue: 7
Page: 838-846
Authors: P. Tagliaferri, M. Rossi, M. T. Di Martino, N. Amodio, E. Leone, A. Gulla, A. Neri and P. Tassone

Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma

Journal: Current Cancer Therapy Reviews
Volume: 10,Issue: 2
Page: 70-79
Authors: Giada Bianchi and Irene M. Ghobrial

Multiple Myeloma and the Immune Microenvironment

Journal: Current Cancer Drug Targets
Volume: 17,Issue: 9
Page: 806-818
Authors: Yawara Kawano, Aldo. M. Roccaro, Irene M. Ghobrial* and Jamil Azzi*

Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment

Journal: Current Cancer Drug Targets
Volume: 17,Issue: 9
Page: 819-838
Authors: Cirino Botta, Maria Cuce, Daniele Caracciolo, Lucia Fiorillo, Pierosandro Tagliaferri and Pierfrancesco Tassone*

Multiple Myeloma Bone Marrow Niche

Journal: Current Pharmaceutical Biotechnology
Volume: 10,Issue: 3
Page: 335-346
Authors: Grzegorz Wladyslaw Basak, Anand S. Srivastava, Rakesh Malhotra and Ewa Carrier

P-Selectin Glycoprotein Ligand-1 as a Potential Target for Humoral Immunotherapy of Multiple Myeloma (Supplementry Material)

Journal: Current Cancer Drug Targets
Volume: 9,Issue: 5
Page: 617-625
Authors: C. Tripodo, A. M. Florena, P. Macor, A. Di Bernardo, R. Porcasi, C. Guarnotta, S. Ingrao, M. Zerilli, E. Secco, M. Todaro, F. Tedesco and V. Franco

Multiple Myeloma: A Paradigm for Translation of the Cancer Stem Cell Hypothesis

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 10,Issue: 2
Page: 116-120
Authors: Jasmin Roya Agarwal and William Matsui

Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function

Journal: Current Cancer Drug Targets
Volume: 10,Issue: 2
Page: 155-167
Authors: A. K. Gandhi, J. Kang, L. Capone, A. Parton, L. Wu, L. H. Zhang, D. Mendy, A. Lopez-Girona, T. Tran, L. Sapinoso, W. Fang, S. Xu, G. Hampton, J. B. Bartlett and P. Schafer

Proteasome Inhibitors and Modulators of Angiogenesis in Multiple Myeloma

Journal: Current Medicinal Chemistry
Volume: 18,Issue: 34
Page: 5185-5195
Authors: M. Ferrarini and E. Ferrero

Role of Active Drug Transporters in Refractory Multiple Myeloma

Journal: Current Topics in Medicinal Chemistry
Volume: 9,Issue: 2
Page: 218-224
Authors: Marco Tucci, Cosima Quatraro, Franco Dammacco and Franco Silvestris

Targeting the IL-6 Pathway in Multiple Myeloma and its Implications in Cancer-Associated Gene Hypermethylation

Journal: Medicinal Chemistry
Volume: 7,Issue: 5
Page: 473-479
Authors: Susan Blaydes Ingersoll, Sarfraz Ahmad, Natalie D. Thoni, Farhana H. Ahmed, Kimberly A. Monahan and John R. Edwards

Molecular Targets for the Treatment of Multiple Myeloma

Journal: Current Cancer Drug Targets
Volume: 12,Issue: 7
Page: 757-767
Authors: Marco Rossi, Maria Teresa Di Martino, Eugenio Morelli, Marzia Leotta, Antonietta Rizzo, Anna Grimaldi, Gabriella Misso, Pierfrancesco Tassone and Michele Caraglia

Azidothymidine is Effective Against Human Multiple Myeloma: A New Use for an Old Drug?

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 13,Issue: 1
Page: 186-192
Authors: Juliana Pereira, Debora Levy, Jorge L.M. Ruiz, Graciela A. Brocardo, Kleber A. Ferreira, Renata O. Costa, Rodrigo G. Queiroz, Durvanei A. Maria, Abrahao E. Hallack Neto, Dalton A.F. Chamone and Sergio P. Bydlowski

IL-6 Activated JAK/STAT3 Pathway and Sensitivity to Hsp90 Inhibitors in Multiple Myeloma

Journal: Current Medicinal Chemistry
Volume: 21,Issue: 26
Page: 3042-3047
Authors: I. Kolosenko, D. Grander and K.P. Tamm

The Effects of 5-Aza-2`-Deoxycytidine on DLC-1 Gene Expression, Methylation Level and Expression of Downstream Signaling Molecules Cdc42 in Multiple Myeloma

Journal: Current Signal Transduction Therapy
Volume: 10,Issue: 1
Page: 31-35
Authors: Xianqi Feng, Ling Zhang, Shumin Nie, Zhan Su, Xue Shi, Yan Gao, Xiangyun Chen, Wenyuan Niu, Zhongguang Cui, Hongguo Zhao, Fanjun Meng and Chunting Zhao

Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 17,Issue: 9
Page: 1267-1277
Authors: Ximena Camacho, Camila Longo Machado, Maria Fernanda García, Marcelo Fernández, Natalia Oddone, Juan Benech, Juan Pablo Gambini, Hugo Cerecetto, Roger Chammas, Pablo Cabral and Eloisa Riva*

Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma

Journal: Cardiovascular & Hematological Disorders-Drug Targets
Volume: 13,Issue: 1
Page: 16-34
Authors: Ota Fuchs

Editorial [Hot Topic: Novel Agents for Multiple Myeloma Treatment (Guest Editors: D. Ribatti and A. Vacca)]

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 6
Page: 395-395
Authors: Domenico Ribatti and Angelo Vacca

Immunomodulatory Drugs as a Therapy for Multiple Myeloma

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 6
Page: 415-421
Authors: H. De Raeve and K. Vanderkerken


Aberrant Immunoglobulin Variations as Indicators of Eventual Clonal Changes in Symptomatic Multiple Myeloma Patients' Course

Journal: Current Cancer Therapy Reviews
Volume: 10,Issue: 2
Page: 90-96
Authors: Eftychia Nikolaou, Efstathios Koulieris, Dimitrios Maltezas, Aikaterini Sarris, Theodoros Iliakis, Nora-Athina Vyniou, Ioanna Vardounioti, Vasiliki Karali, Ilias Pessach, Anna Efthymiou, Aikaterini Bitsani, Vasiliki Bartzis, Tatiana Tzenou, Maria Dimou, Theodoros P. Vassilakopoulos, Maria M. Angelopoulou, Panagiotis Tsaftaridis, Kalliroi Tsalimalma, Nikolitsa Kafasi, Panayiotis Panayiotidis and Marie-Christine Kyrtsonis

Triptolide Induces Cell Apoptosis by Targeting H3K4me3 and Downstream Effector Proteins in KM3 Multiple Myeloma Cells

Journal: Current Pharmaceutical Biotechnology
Volume: 17,Issue: 2
Page: 147-160
Authors: Lu Wen, Yan Chen, Ling L. Zeng, Fei Zhao, Sha Yi, Li J. Yang, Ben P. Zhang, Jie Zhao, Zi C. Zhao and Chun Zhang

Second Generation Proteasome Inhibitors in Multiple Myeloma

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 17,Issue: 7
Page: 920-926
Authors: Alessandro Gozzetti*, Giulia Papini, Veronica Candi, Corrado Zuanelli Brambilla, Santina Sirianni and Monica Bocchia

Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress

Journal: Current Medicinal Chemistry
Volume: 21,Issue: 28
Page: 3271-3280
Authors: H. Fu, H. Fang, Jie Sun, H. Wang, A. Liu, J. Sun and Z. Wu

Prevalence of Neuropathy Associated With Bortezomib: A Retrospective Study

Journal: Clinical Cancer Drugs
Volume: 4,Issue: 1
Page: 69-72
Authors: Pulivarthi Swaroopa, Mathew Josy, Ehresmann Kirsten and Gurram Murali Krishna*

Antiangiogenic Therapy in Hematologic Malignancies

Journal: Current Pharmaceutical Design
Volume: 10,Issue: 11
Page: 1221-1234
Authors: Moehler T. M., Hillengass J., Goldschmidt H. and Ho A. D.

Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies

Journal: Current Drug Targets
Volume: 7,Issue: 10
Page: 1341-1347
Authors: Constantine S. Mitsiades, Nicholas Mitsiades, Teru Hideshima, Paul G. Richardson and Kenneth C. Anderson

Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions

Journal: Current Medicinal Chemistry
Volume: 18,Issue: 11
Page: 1584-1598
Authors: V.T. Labropoulou, A.D. Theocharis, A. Symeonidis, S.S. Skandalis, N.K. Karamanos and H.P. Kalofonos

Bisphosphonates in Lung Cancer: Can They Provide Benefits Beyond Prevention of Skeletal Morbidity?

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 12,Issue: 2
Page: 137-143
Authors: Vera Hirsh

Stem Cell Transplant and Idiotypic Vaccination for B-Cell Malignancies

Journal: Current Topics in Medicinal Chemistry
Volume: 11,Issue: 13
Page: 1653-1660
Authors: Maurizio Bendandi, Fernando Pastor, Jose' Nieto, Elena Soria, Helena Villanueva, Antonia Sampol, Ascension Lopez-Diaz de Cerio and Susana Inoges

The Immunoproteasome as a Therapeutic Target for Hematological Malignancies

Journal: Current Cancer Drug Targets
Volume: 14,Issue: 6
Page: 537-548
Authors: Zachary Miller, Wooin Lee and Kyung Bo Kim

Exploring Old Drugs for the Treatment of Hematological Malignancies

Journal: Current Medicinal Chemistry
Volume: 18,Issue: 10
Page: 1509-1514
Authors: F. Gan, B. Cao, D. Wu, Z. Chen, T. Hou and X. Mao

Bortezomib: Proteasome Inhibition as a Novel Mechanism of Cancer Therapy-Implications for Hematological Malignancies

Journal: Letters in Drug Design & Discovery
Volume: 4,Issue: 2
Page: 82-86
Authors: Joesph Mikhael and Hong Chang

Thalidomide: Chemistry, Therapeutic Potential and Oxidative Stress Induced Teratogenicity

Journal: Current Topics in Medicinal Chemistry
Volume: 12,Issue: 13
Page: 1436-1455
Authors: Neeraj Kumar, Upendra Sharma, Chitra Singh and Bikram Singh

Targeting Angiogenesis in the Treatment of Multiple

Journal: Current Angiogenesis (Discontinued)
Volume: 3,Issue: 1
Page: 39-47
Authors: Najib Dally and Elizabeth Eshel

Proteasome as an Emerging Therapeutic Target in Cancer

Journal: Current Pharmaceutical Design
Volume: 13,Issue: 5
Page: 471-485
Authors: I. Zavrski, L. Kleeberg, M. Kaiser, C. Fleissner, U. Heider, J. Sterz, C. Jakob and O. Sezer

Bortezomib in the Treatment of Cancer

Journal: Recent Patents on Anti-Cancer Drug Discovery
Volume: 1,Issue: 3
Page: 397-403
Authors: Aldo M. Roccaro, Angelo Vacca and Domenico Ribatti

Palmitoylethanolamide Restores Myelinated-Fibre Function in Patients with Chemotherapy-Induced Painful Neuropathy

Journal: CNS & Neurological Disorders - Drug Targets
Volume: 10,Issue: 8
Page: 916-920
Authors: A. Truini, A. Biasiotta, G. Di Stefano, S. La Cesa, C. Leone, C. Cartoni, V. Federico, M. T. Petrucci and G. Cruccu

Drug Combinations with Proteasome Inhibitors in Antitumor Therapy

Journal: Current Pharmaceutical Design
Volume: 19,Issue: 22
Page: 4094-4114
Authors: Laura Gatti, Valentina Zuco, Nadia Zaffaroni and Paola Perego

Marizomib, A Potent Second Generation Proteasome Inhibitor from Natural Origin

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 15,Issue: 3
Page: 298-306
Authors: Long Ma and Aipo Diao

Targeting Pathways Mediating Bone Disease

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 6
Page: 423-429
Authors: Nicola Giuliani, Francesca Morandi, Sara Tagliaferri and Vittorio Rizzoli

Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 8,Issue: 7
Page: 798-806
Authors: Andrea Bortolato, Giorgio Cozza and Stefano Moro

The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib

Journal: Current Pharmaceutical Design
Volume: 17,Issue: 15
Page: 1483-1499
Authors: Boris Cvek and Zdenek Dvorak

Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction

Journal: Current Pharmaceutical Design
Volume: 19,Issue: 18
Page: 3190-3200
Authors: Biyin Cao, Jie Li and Xinliang Mao

Proteasome Inhibition in Transplantation-Focusing on the Experience with Bortezomib

Journal: Current Pharmaceutical Design
Volume: 19,Issue: 18
Page: 3299-3304
Authors: Yong Liang and Haiyan Liu

Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug

Journal: Current Medicinal Chemistry
Volume: 20,Issue: 33
Page: 4102-4108
Authors: Shuang Zhou, Fengfei Wang, Tze-Chen Hsieh, Joseph M. Wu and Erxi Wu

Pathophysiology of Metastatic Bone Disease and the Role of the Second Generation of Bisphosphonates: From Basic Science to Medicine

Journal: Current Pharmaceutical Design
Volume: 22,Issue: 11
Page: 1546-1557
Authors: Reham F. Barghash and Wafaa M. Abdou

New Tubulin Polymerization Inhibitor Derived from Thalidomide: Implications for Anti-Myeloma Therapy

Journal: Current Medicinal Chemistry
Volume: 15,Issue: 8
Page: 754-765
Authors: Masahiro Kizaki and Yuichi Hashimoto

Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells

Journal: Cardiovascular & Hematological Disorders-Drug Targets
Volume: 9,Issue: 1
Page: 62-77
Authors: Ota Fuchs, Dana Provaznikova, Iuri Marinov, Katerina Kuzelova and Ivan Spicka

The JAK-STAT Pathway: A Therapeutic Target in Hematological Malignancies

Journal: Current Cancer Drug Targets
Volume: 6,Issue: 8
Page: 671-679
Authors: A. Ferrajoli, S. Faderl, F. Ravandi and Z. Estrov

Bortezomib as an Antitumor Agent

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 6
Page: 441-448
Authors: A. M. Roccaro, T. Hideshima, P. G. Richardson, D. Russo, D. Ribatti, A. Vacca, F. Dammacco and K. C. Anderson

Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 7,Issue: 3
Page: 359-365
Authors: Yuki Ishii, Samuel Waxman and Doris Germain

The Immunoproteasome: An Emerging Therapeutic Target

Journal: Current Topics in Medicinal Chemistry
Volume: 11,Issue: 23
Page: 2923-2930
Authors: Wooin Lee and Kyung Bo Kim

Tumor Bone Diseases: Molecular Mechanisms and Opportunities for Novel Treatments

Journal: Current Medicinal Chemistry-Anti-Cancer Agents
Volume: 1,Issue: 3
Page: 313-329
Authors: Mira Susa, Markus Glatt and Anna Teti

Inhibitors of the Ubiquitin-Proteasome System and the Cell Death Machinery: How Many Pathways are Activated?

Journal: Current Molecular Pharmacology
Volume: 1,Issue: 1
Page: 24-37
Authors: Claudio Brancolini

Novel Agents in CNS Myeloma Treatment

Journal: Central Nervous System Agents in Medicinal Chemistry
Volume: 14,Issue: 1
Page: 23-27
Authors: Alessandro Gozzetti and Alfonso Cerase

Curcumin Targets in Inflammation and Cancer

Journal: Endocrine, Metabolic & Immune Disorders-Drug Targets
Volume: 15,Issue: 2
Page: 88-96
Authors: Atsuko Deguchi

ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology

Journal: Current Medicinal Chemistry
Volume: 15,Issue: 10
Page: 978-990
Authors: R. Schmidmaier and P. Baumann

Anti-Tumour Effects of Bisphosphonates - What have we Learned from In Vivo Models?

Journal: Current Cancer Drug Targets
Volume: 9,Issue: 7
Page: 807-823
Authors: H. K. Brown and I. Holen

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

Journal: Current Cancer Drug Targets
Volume: 11,Issue: 3
Page: 239-253
Authors: D. Chen, M. Frezza, S. Schmitt, J. Kanwar and Q. P. Dou

Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

Journal: Current Cancer Drug Targets
Volume: 11,Issue: 3
Page: 254-284
Authors: B. C. Potts, M. X. Albitar, K. C. Anderson, S. Baritaki, C. Berkers, B. Bonavida, J. Chandra, D. Chauhan, J. C. Cusack, W. Fenical, I. M. Ghobrial, M. Groll, P. R. Jensen, K. S. Lam, G. K. Lloyd, W. McBride, D. J. McConkey, C. P. Miller, S. T.C. Neuteboom, Y. Oki, H. Ovaa, F. Pajonk, P. G. Richardson, A. M. Roccaro, C. M. Sloss, M. A. Spear, E. Valashi, A. Younes and M. A. Palladino

Dasatinib: An Anti-Tumour Agent via Src Inhibition

Journal: Current Drug Targets
Volume: 12,Issue: 4
Page: 563-578
Authors: Antonio Gnoni, Ilaria Marech, Nicola Silvestris, Angelo Vacca and Vito Lorusso

Modulating Mesenchymal Stromal Cell Function with Cholesterol Synthesis Inhibitors

Journal: Current Medicinal Chemistry
Volume: 18,Issue: 34
Page: 5196-5205
Authors: A. Poggi and M. R. Zocchi

Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies

Journal: Current Topics in Medicinal Chemistry
Volume: 6,Issue: 16
Page: 1657-1686
Authors: Gerassimos A. Pangalis, Marie-Christine Kyrtsonis, Theodoros P. Vassilakopoulos, Maria N. Dimopoulou, Marina P. Siakantaris, Christos Emmanouilides, Dimitris Doufexis, Sotirios Sahanas, Flora N. Kontopidou, Christina Kalpadakis, Maria K. Angelopoulou, Evangelia M. Dimitriadou, Styliani I. Kokoris and Panayiotis Panayiotidis

Expression and Function of the Transient Receptor Potential Ion Channel Family in the Hematologic Malignancies

Journal: Current Molecular Pharmacology
Volume: 6,Issue: 3
Page: 137-148
Authors: Maria B. Morelli, Sonia Liberati, Consuelo Amantini, Massimo Nabiss, Matteo Santoni, Valerio Farfariello and Giorgio Santoni

The Role of P2X Receptors in Bone Biology

Journal: Current Medicinal Chemistry
Volume: 22,Issue: 7
Page: 902-914
Authors: N.R. Jørgensen, S. Syberg and M. Ellegaard

Thalidomide: An Overview of its Pharmacological Mechanisms of Action

Journal: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Volume: 5,Issue: 1
Page: 71-77
Authors: Elizabeth P. Sampaio, Daniel S. Carvalho, Jose A. C. Nery, Ulisses G. Lopes and Euzenir N. Sarno

Allosteric Regulators of the Proteasome: Potential Drugs and a Novel Approach for Drug Design

Journal: Current Medicinal Chemistry
Volume: 13,Issue: 2
Page: 155-165
Authors: Xiaolin Tan, Pawel A. Osmulski and Maria Gaczynska

Focal Adhesion Kinase as a Therapeutic Target of Bortezomib

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 10,Issue: 10
Page: 747-752
Authors: Bor-Sheng Ko, Tzu-Ching Chang and Jun-Yang Liou

Pycnodysostosis: Role and Regulation of Cathepsin K in Osteoclast Function and Human Disease

Journal: Current Molecular Medicine
Volume: 2,Issue: 5
Page: 407-421
Authors: Gabriela Motyckova and David E. Fisher

Ubiquitylation and Cancer Development

Journal: Current Cancer Drug Targets
Volume: 8,Issue: 2
Page: 118-123
Authors: John Silke, Maria Miasari and Hamsa Puthalakath

Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise

Journal: Current Pharmaceutical Design
Volume: 14,Issue: 21
Page: 2051-2060
Authors: M. P. Bernard, S. Bancos, P. J. Sime and R. P. Phipps

“Cancer Antigen WT1 Protein-Derived Peptide”-Based Treatment of Cancer -Toward the Further Development

Journal: Current Medicinal Chemistry
Volume: 15,Issue: 29
Page: 3052-3061
Authors: Yoshihiro Oka, Akihiro Tsuboi, Fumihiro Fujiki, Toshiaki Shirakata, Sumiyuki Nishida, Naoki Hosen, Hiroko Nakajima, Zheyu Li, Ichiro Kawase, Yusuke Oji and Haruo Sugiyama

Proteasome Regulators: Activators and Inhibitors

Journal: Current Medicinal Chemistry
Volume: 16,Issue: 8
Page: 931-939
Authors: Li Huang and Chin Ho Chen

Chromatin Structure and Epigenetics of Tumour Cells: A Review

Journal: Cardiovascular & Hematological Disorders-Drug Targets
Volume: 9,Issue: 1
Page: 51-61
Authors: Eva Bartova, Jana Krejci, Roman Hajek, Andrea Harnicarova and Stanislav Kozubek

The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 9,Issue: 5
Page: 550-559
Authors: Kiyotaka Kawauchi, Toshie Ogasawara, Masako Yasuyama, Kuniaki Otsuka and Osamu Yamada

Proteasome Inhibitors in Cancer Therapy

Journal: Current Drug Targets
Volume: 10,Issue: 10
Page: 968-981
Authors: Ugo Testa

Statins as Either Immunomodulators or Anti-Cancer Drugs: Functional Activities on Tumor Stromal Cells and Natural Killer Cells

Journal: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Volume: 9,Issue: 1
Page: 82-92
Authors: Alessandro Poggi, Alessandra Musso, Silvia Boero, Paolo Canevali and Maria Raffaella Zocchi

Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma

Journal: Current Pharmaceutical Design
Volume: 16,Issue: 11
Page: 1272-1283
Authors: C.H. Buckle, H.L. Neville-Webbe, P.I. Croucher and M.A. Lawson

Combination Therapy with Arsenic Trioxide for Hematological Malignancies

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 10,Issue: 6
Page: 504-510
Authors: Shinichiro Takahashi

Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)

Journal: Current Cancer Drug Targets
Volume: 11,Issue: 3
Page: 285-295
Authors: D. J. Kuhn, R. Z. Orlowski and C. C. Bjorklund

Adjuvant Zoledronic Acid Reduces Disease Recurrence in Breast Cancer: Antitumor Effects on the Seed and the Soil

Journal: Current Cancer Therapy Reviews
Volume: 7,Issue: 2
Page: 111-118
Authors: Michael Gnant

Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 12,Issue: 2
Page: 102-113
Authors: Philippe Clezardin

Bisphosphonate Anticancer Activity in Prostate Cancer and Other Genitourinary Cancers

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 12,Issue: 2
Page: 129-136
Authors: Fred Saad and Peter Mulders

Inhibitory Effects of Bisphosphonates on the Proliferation of Human Ovarian Cancer Cell Lines and the Mechanism

Journal: Medicinal Chemistry
Volume: 2,Issue: 3
Page: 223-226
Authors: Hiroshi Seto, Tsunekazu Kita, Junko Hirata, Yoshihiro Kikuchi and Kazuya Kudoh

Bcl-2-Targeted Antisense Therapy (Oblimersen Sodium): Towards Clinical Reality

Journal: Reviews on Recent Clinical Trials
Volume: 1,Issue: 3
Page: 217-235
Authors: Joao Nuno Moreira, Adriana Santos and Sergio Simoes

Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells

Journal: Current Immunology Reviews
Volume: 3,Issue: 1
Page: 41-55
Authors: Elke De Bruyne, Eline Menu, Els Van Valckenborgh, Hendrik De Raeve, Ben Van Camp, Ivan Van Riet and Karin Vanderkerken

Use of Systemic Proteasome Inhibition as an Immune-Modulating Agent in Disease

Journal: Endocrine, Metabolic & Immune Disorders-Drug Targets
Volume: 7,Issue: 1
Page: 29-34
Authors: Lauren H. Mattingly, Ruth A. Gault and William J. Murphy

Thalidomide Analogues as Anticancer Drugs

Journal: Recent Patents on Anti-Cancer Drug Discovery
Volume: 2,Issue: 2
Page: 167-174
Authors: Jeanny B. Aragon-Ching, Haiqing Li, Erin R. Gardner and William D. Figg

Bisphosphonate Osteonecrosis (BON): Unanswered Questions and Research Possibilities

Journal: Reviews on Recent Clinical Trials
Volume: 4,Issue: 2
Page: 99-109
Authors: Cesar A. Migliorati, Mark M. Schubert and Douglas E. Peterson

Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry

Journal: Current Topics in Medicinal Chemistry
Volume: 10,Issue: 3
Page: 232-256
Authors: E. Genin, M. Reboud-Ravaux and J. Vidal

About the Editor

Journal: Current Organic Synthesis
Volume: 7,Issue: 4
Page: 310-310
Authors: Bentham Science Publishers

Serine-Threonine Protein Kinases CK1, CK2 and GSK3 in Normal and Malignant Haematopoiesis

Journal: Current Signal Transduction Therapy
Volume: 6,Issue: 1
Page: 88-98
Authors: Francesco Piazza, Sabrina Manni, Anna Colpo, Laura Quotti Tubi, Carmela Gurrieri and Gianpietro Semenzato

A Novel Technology for Hematopoietic Stem Cell Expansion Using Combination of Nanofiber and Growth Factors

Journal: Recent Patents on Nanotechnology
Volume: 4,Issue: 2
Page: 125-134
Authors: Jingwei Lu, Reeva Aggarwal, Vincent J. Pompili and Hiranmoy Das

Immunomodulatory Properties of Thalidomide Analogs: Pomalidomide and Lenalidomide, Experimental and Therapeutic Applications

Journal: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Volume: 5,Issue: 3
Page: 192-196
Authors: Pawel Bodera and Wanda Stankiewicz

Thalidomide: A Banned Drug Resurged into Future Anticancer Drug

Journal: Current Drug Therapy
Volume: 7,Issue: 1
Page: 13-23
Authors: Imran Ali, Waseem A. Wani, Kishwar Saleem and Ashanul Haque

Chemistry and Pharmacology of Imexon and Related Cyanoaziridines

Journal: Current Medicinal Chemistry
Volume: 19,Issue: 33
Page: 5745-5753
Authors: W.A. Remers and R.T. Dorr

Integrative Approaches for microRNA Target Prediction: Combining Sequence Information and the Paired mRNA and miRNA Expression Profiles

Journal: Current Bioinformatics
Volume: 8,Issue: 1
Page: 37-45
Authors: Naifang Su, Minping Qian and Minghua Deng

Targeting the Ubiquitin E1 as a Novel Anti-Cancer Strategy

Journal: Current Pharmaceutical Design
Volume: 19,Issue: 18
Page: 3201-3209
Authors: Wei Xu, Julie L. Lukkarila, Sara R. da Silva, Stacey-Lynn Paiva, Patrick T. Gunning and Aaron D. Schimmer

Deubiquitinating Enzymes as Therapeutic Targets in Cancer

Journal: Current Pharmaceutical Design
Volume: 19,Issue: 22
Page: 4039-4052
Authors: Key-Hwan Lim and Kwang-Hyun Baek

Non-Covalent Proteasome Inhibitors

Journal: Current Pharmaceutical Design
Volume: 19,Issue: 22
Page: 4115-4130
Authors: Julia Kaffy, Guillaume Bernadat and Sandrine Ongeri

The Role of miRNAs in Plasma Cell Dyscrasias

Journal: MicroRNA
Volume: 2,Issue: 3
Page: 165-173
Authors: Siobhan Glavey, Salomon Manier, Antonio Sacco, Giuseppe Rossi, Irene M. Ghobrial and Aldo M. Roccaro

Editorial (Thematic Issue: Recent Advances in Proteasome Inhibitor-Based Cancer Therapies)

Journal: Current Cancer Drug Targets
Volume: 14,Issue: 6
Page: 505-505
Authors: Q. Ping Dou

Bone Metastasis-Related MicroRNAs: New Targets for Treatment?

Journal: Current Cancer Drug Targets
Volume: 15,Issue: 8
Page: 716-725
Authors: Qian Zhao, Fengming Luo, Junrong Ma and Xijie Yu

Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases

Journal: Current Medicinal Chemistry
Volume: 23,Issue: 12
Page: 1217-1238
Authors: Roberta Ettari, Santo Previti, Alessandra Bitto, Silvana Grasso and Maria Zappalà

Cancer Associated Thrombosis: Focus on Prevention and Treatment of Venous Thromboembolism

Journal: Cardiovascular & Hematological Agents in Medicinal Chemistry
Volume: 14,Issue: 2
Page: 101-112
Authors: Kyaw Z. Thein, Zin W. Myint, Aung M. Tun and Thein H. Oo

Mevalonate Pathway and Human Cancers

Journal: Current Molecular Pharmacology
Volume: 10,Issue: 2
Page: 77-85
Authors: Seyedeh Zahra Bathaie, Mahboobeh Ashrafi, Mahshid Azizian and Fuyuhiko Tamanoi

Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity

Journal: Current Topics in Medicinal Chemistry
Volume: 16,Issue: 4
Page: 427-434
Authors: Shabir Ahmad Ganai

Deep Venous Thrombosis Associated with Thalidomide use in a Case of Steroid Dependent Erythema Nodosum Leprosum-a Management Conundrum

Journal: Current Drug Safety
Volume: 12,Issue: 2
Page: 140-144
Authors: Upinder Kaur, Sankha Shubhra Chakrabarti, Rohit Singh and Indrajeet Singh Gambhir*

3D-QSAR Modeling and Molecular Docking Study on Small Molecule Stat3 Inhibitors, Src Homology 2 Domain Binders

Journal: Letters in Drug Design & Discovery
Volume: 14,Issue: 1
Page: 36-49
Authors: Jing Li Wang, Li Ping Cheng, Yang Ping Quan, Zhen Wang, Fan Hong Wu and Wei Deng

Editorial (Thematic Issue: “miRNA and Cancer; Computational and Experimental Approaches”)

Journal: Current Pharmaceutical Biotechnology
Volume: 15,Issue: 5
Page: 429-429
Authors: Yusuf Tutar

Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy

Journal: Current Signal Transduction Therapy
Volume: 1,Issue: 1
Page: 25-52
Authors: Bharat B. Aggarwal, Gautam Sethi, Asha Nair and Haruyo Ichikawa

Natural Products Inhibiting the Ubiquitin-Proteasome Proteolytic Pathway, A Target for Drug Development

Journal: Current Medicinal Chemistry
Volume: 13,Issue: 7
Page: 745-754
Authors: Sachiko Tsukamoto and Hideyoshi Yokosawa

Hsp90: A Novel Target for Cancer Therapy

Journal: Current Topics in Medicinal Chemistry
Volume: 6,Issue: 11
Page: 1205-1214
Authors: David B. Solit and Neal Rosen

Current status of Immunotherapy in B Cell Malignancies

Journal: Current Drug Targets
Volume: 7,Issue: 10
Page: 1371-1374
Authors: D. M. Kofler, C. Mayr and C.-M. Wendtner

Interferons: Mechanisms, Biological Activities and Survey of their Use in Human Diseases

Journal: Current Bioactive Compounds
Volume: 2,Issue: 4
Page: 431-444
Authors: Dalia Obeid and Brigitte Bauvois

Targeting the EGFR Pathway for Cancer Therapy

Journal: Current Medicinal Chemistry
Volume: 13,Issue: 29
Page: 3483-3492
Authors: James B. Johnston, Sri Navaratnam, Marshall W. Pitz, Jerry M. Maniate, Emilia Wiechec, Heinrich Baust, Joel Gingerich, Georgios P. Skliris, Leigh C. Murphy and Marek Los

Arsenic Trioxide in Hematological Malignancies: The New Discovery of an Ancient Drug

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 6
Page: 397-405
Authors: A. Bonati, V. Rizzoli and P. Lunghi

Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation

Journal: Current Pharmaceutical Design
Volume: 11,Issue: 3
Page: 395-401
Authors: Kozo Yasui, Norimoto Kobayashi, Takashi Yamazaki and Kazunaga Agematsu

Novel Molecular Targets for Systemic Lupus Erythematosus

Journal: Current Drug Targets
Volume: 3,Issue: 3
Page: 223-228
Authors: Maria Marino, Maria Rossi, Menotti Ruvo and Giorgio Fassina

Integrins as Novel Drug Targets for Overcoming Innate Drug Resistance

Journal: Current Cancer Drug Targets
Volume: 2,Issue: 1
Page: 37-43
Authors: Jason S. Damiano

The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases

Journal: Cardiovascular & Hematological Disorders-Drug Targets
Volume: 7,Issue: 4
Page: 250-273
Authors: Imtiaz M. Shah and Mario Di Napoli

Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?

Journal: Current Medicinal Chemistry
Volume: 15,Issue: 29
Page: 3025-3035
Authors: A. Gilardini, P. Marmiroli and G. Cavaletti

17 AAG for HSP90 Inhibition in Cancer – From Bench to Bedside

Journal: Current Molecular Medicine
Volume: 9,Issue: 5
Page: 654-664
Authors: Saad Z. Usmani, Robert Bona and Zihai Li

WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 9,Issue: 7
Page: 787-797
Authors: Yoshihiro Oka, Akihiro Tsuboi, Fumihiro Fujiki, Zheyu Li, Hiroko Nakajima, Naoki Hosen, Toshiaki Shirakata, Sumiyuki Nishida, Yusuke Oji, Ichiro Kawase and Haruo Sugiyama

Bisphosphonates in the Prevention of Disease Recurrence: Current Results and Ongoing Trials

Journal: Current Cancer Drug Targets
Volume: 9,Issue: 7
Page: 824-833
Authors: M. Gnant

Idiotype Vaccines for Human B-Cell Malignancies

Journal: Current Pharmaceutical Design
Volume: 16,Issue: 3
Page: 300-307
Authors: S. Inoges, A. Lopez-Diaz de Cerio, E. Soria, H. Villanueva, F. Pastor and M. Bendandi

Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment

Journal: Current Cancer Drug Targets
Volume: 10,Issue: 1
Page: 55-67
Authors: A. Russo, G. Bronte, F. Fulfaro, G. Cicero, V. Adamo, N. Gebbia and S. Rizzo

SCF E3 Ubiquitin Ligases as Anticancer Targets

Journal: Current Cancer Drug Targets
Volume: 11,Issue: 3
Page: 347-356
Authors: L. Jia and Y. Sun

Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms

Journal: Current Pharmaceutical Design
Volume: 17,Issue: 3
Page: 256-271
Authors: Jozefa Wasierska-Gadek and Margarita Maurer

The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 11,Issue: 2
Page: 242-246
Authors: James J. Driscoll, Alex Minter, Daniel A. Driscoll and Jason K. Burris

Lenalidomide – Current Understanding of Mechanistic Properties

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 11,Issue: 3
Page: 315-326
Authors: Nishant Tageja

Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic

Journal: Current Pharmaceutical Design
Volume: 17,Issue: 19
Page: 1970-1978
Authors: Andrew P. Mazar, Richard W. Ahn and Thomas V. O'Halloran

Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway

Journal: Current Drug Targets
Volume: 12,Issue: 11
Page: 1581-1594
Authors: John S. Schneekloth and Craig M. Crews

Development and Validation of a Rapid and Sensitive Assay for Simultaneous Quantification of Lenalidomide and Dexamethasone in Human Plasma by Liquid Chromatography Coupled to Tandem Mass-Spectrometry

Journal: Current Pharmaceutical Analysis
Volume: 7,Issue: 4
Page: 240-247
Authors: Shanmugam Gopinath, Ramadass S. Kumar, Sekar Alexander and Palanisamy Danabal

Future Prospects for Old Chemotherapeutic Drugs in the Target-Specific Era; Pharmaceutics, Combinations, Co-Drugs and Prodrugs with Melphalan as an Example

Journal: Letters in Drug Design & Discovery
Volume: 3,Issue: 10
Page: 695-703
Authors: M. Wickstrom, H. Lovborg and J. Gullbo

Potential Clinical Applications of the CXCR4 Antagonist Bicyclam AMD3100

Journal: Mini-Reviews in Medicinal Chemistry
Volume: 5,Issue: 9
Page: 805-824
Authors: Erik De Clercq

Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine

Journal: Recent Patents on Anti-Cancer Drug Discovery
Volume: 4,Issue: 1
Page: 54-72
Authors: Madeleine Hewish, Ian Chau and David Cunningham

Thromboembolic Complications in Malignant Haematological Disorders

Journal: Current Vascular Pharmacology
Volume: 8,Issue: 4
Page: 482-494
Authors: Roberto Castelli, Barbara Ferrari, Agostino Cortelezzi and Achille Guariglia

Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy

Journal: Current Signal Transduction Therapy
Volume: 6,Issue: 1
Page: 44-54
Authors: Ota Fuchs

ATP Site-Directed Inhibitors of Protein Kinase CK2: An Update

Journal: Current Topics in Medicinal Chemistry
Volume: 11,Issue: 11
Page: 1340-1351
Authors: S. Sarno, E. Papinutto, C. Franchin, J. Bain, M. Elliott, F. Meggio, Z. Kazimierczuk, A. Orzeszko, G. Zanotti, R. Battistutta and L. A. Pinna

Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy

Journal: Current Topics in Medicinal Chemistry
Volume: 11,Issue: 23
Page: 2888-2905
Authors: Michael Frezza, Sara Schmitt and Q. Ping Dou

Recombinant Adenovirus-mediated Cytotoxic Gene Therapy and Lymphoproliferative Disorders: Analysis Based on Pharmacodynamics

Journal: Current Drug Target - Immune, Endocrine & Metabolic Disorders
Volume: 2,Issue: 2
Page: 109-118
Authors: Francesco Turturro

Inhibitor at the Gates, Inhibitor in the Chamber: Allosteric and Competitive Inhibitors of the Proteasome as Prospective Drugs

Journal: Current Medicinal Chemistry-Immunology, Endocrine & Metabolic Agents
Volume: 2,Issue: 4
Page: 279-301
Authors: M. Gaczynska and P.A. Osmulski


Cyclin-Dependent Kinase Inhibition by Flavoalkaloids

Journal: Mini-Reviews in Medicinal Chemistry
Volume: 12,Issue: 7
Page: 632-649
Authors: S. K. Jain, S. B. Bharate and R. A. Vishwakarma

CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges

Journal: Recent Patents on Anti-Cancer Drug Discovery
Volume: 7,Issue: 3
Page: 251-264
Authors: Filomena de Nigris, Concetta Schiano, Teresa Infante and Claudio Napoli

The Proteasome in Health and Disease

Journal: Current Pharmaceutical Design
Volume: 19,Issue: 6
Page: 1010-1028
Authors: Elzbieta Jankowska, Julia Stoj, Przemyslaw Karpowicz, Pawel A. Osmulski and Maria Gaczynska

Cullin-RING Ligases as Attractive Anti-cancer Targets

Journal: Current Pharmaceutical Design
Volume: 19,Issue: 18
Page: 3215-3225
Authors: Yongchao Zhao and Yi Sun

From Bortezomib to other Inhibitors of the Proteasome and Beyond

Journal: Current Pharmaceutical Design
Volume: 19,Issue: 22
Page: 4025-4038
Authors: Daniela Buac, Min Shen, Sara Schmitt, Fathima Rani Kona, Rahul Deshmukh, Zhen Zhang, Christine Neslund-Dudas, Bharati Mitra and Q. Ping Dou

Autologus Stem Cell Transplatation as a Care Option in Elderly Patients. A Review

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 13,Issue: 9
Page: 1419-1429
Authors: Lucia Fratino, Maurizio Rupolo, Mario Mazzuccato, Massimiliano Berretta, Arben Lleshi, Umberto Tirelli and Mariagrazia Michieli

Epoxomicin Sensitizes Resistant Osteosarcoma Cells to TRAIL Induced Apoptosis

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 15,Issue: 4
Page: 527-533
Authors: Ferhat Hanikoglu, Aysegul Cort, Hakan Ozben, Aysegul Hanikoglu and Tomris Ozben

Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies

Journal: Clinical Cancer Drugs
Volume: 2,Issue: 2
Page: 100-111
Authors: Benny Johnson and Daruka Mahadevan

Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors

Journal: Current Topics in Medicinal Chemistry
Volume: 16,Issue: 9
Page: 934-947
Authors: Shagun Krishna, Vikash Kumar and Mohammad Imran Siddiqi

Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94

Journal: Current Topics in Medicinal Chemistry
Volume: 16,Issue: 25
Page: 2765-2778
Authors: Ephraim A. Ansa-Addo, Jessica Thaxton, Feng Hong, Bill X. Wu, Yongliang Zhang, Caroline W. Fugle, Alessandra Metelli, Brian Riesenberg, Katelyn Williams, Daniel T. Gewirth, Gabriela Chiosis, Bei Liu and Zihai Li


Nanoparticles of Biodegradable Polymers for Clinical Administration of Paclitaxel

Journal: Current Medicinal Chemistry
Volume: 11,Issue: 4
Page: 413-424
Authors: Si-Shen Feng, Li Mu, Khin Yin Win and Guofeng Huang

Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis

Journal: Current Medicinal Chemistry
Volume: 20,Issue: 38
Page: 4888-4923
Authors: N. S.H.N. Moorthy, S. F. Sousa, M. J. Ramos and P. A. Fernandes

Editorial (Thematic Issue: Signalling Pathways in Anti-cancer Drug Resistance)

Journal: Current Medicinal Chemistry
Volume: 21,Issue: 26
Page: 3007-3008
Authors: Chen Chen, Jiezhong Chen and Kong-Nan Zhao

Results 1 - 201 of 201